What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Enzyme
His scientific interests lie mostly in Internal medicine, Endocrinology, Biochemistry, Lipoprotein and Apolipoprotein B.
Internal medicine is often connected to Diabetes mellitus in his work.
The concepts of his Endocrinology study are interwoven with issues in Chemokine, Receptor, IκB kinase and IκBα.
Lipoprotein is a subfield of Cholesterol that Kerry-Anne Rye tackles.
His studies in Cholesterol integrate themes in fields like Oxidative stress, Efflux, Function and ATP Binding Cassette Transporter 1.
The various areas that Kerry-Anne Rye examines in his Apolipoprotein B study include Phosphatidylcholine, Lecithin, Enzyme, Cell adhesion molecule and Very low-density lipoprotein.
His most cited work include:
- Antiinflammatory Properties of HDL (1019 citations)
- High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules (650 citations)
- High density lipoproteins and coronary heart disease. (376 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Endocrinology, Apolipoprotein B, Cholesterol and Biochemistry.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Diabetes mellitus.
Endocrinology and ABCA1 are frequently intertwined in his study.
His research integrates issues of Very low-density lipoprotein, Apolipoprotein E, Chromatography and Phosphatidylcholine in his study of Apolipoprotein B.
His biological study spans a wide range of topics, including Efflux and Pharmacology.
He interconnects Statin, POPC, Atorvastatin and Immunology in the investigation of issues within Lipoprotein.
He most often published in these fields:
- Internal medicine (95.01%)
- Endocrinology (82.07%)
- Apolipoprotein B (59.15%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (95.01%)
- Endocrinology (82.07%)
- Cholesterol (43.07%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Endocrinology, Cholesterol, Diabetes mellitus and Apolipoprotein B.
His work on Lipoprotein, Inflammation and Biomarker as part of general Internal medicine study is frequently linked to FGF21, bridging the gap between disciplines.
Kerry-Anne Rye regularly links together related areas like ABCA1 in his Endocrinology studies.
Many of his studies involve connections with topics such as Confounding and Cholesterol.
His Diabetes mellitus research incorporates elements of Cholesterol homeostasis and Risk factor.
His Apolipoprotein B research integrates issues from Pregnancy, Hypertension in Pregnancy and Hypertensive disorder.
Between 2016 and 2021, his most popular works were:
- HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology (61 citations)
- Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. (49 citations)
- High-Density Lipoproteins Exert Pro-inflammatory Effects on Macrophages via Passive Cholesterol Depletion and PKC-NF-κB/STAT1-IRF1 Signaling (40 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Enzyme
- Internal medicine
Kerry-Anne Rye mostly deals with Internal medicine, Endocrinology, Cell biology, Cholesterylester transfer protein and Cholesterol.
Kerry-Anne Rye combines topics linked to Diabetes mellitus with his work on Internal medicine.
His Apolipoprotein B and Insulin resistance study in the realm of Endocrinology interacts with subjects such as FGF21.
His Cholesterylester transfer protein study is focused on Lipoprotein and Biochemistry.
His work in the fields of Lipoprotein, such as Torcetrapib, overlaps with other areas such as Neointimal hyperplasia.
His studies deal with areas such as Genetics and Mechanism of action as well as Cholesterol.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
